Breaking News

Oncorus to Build GMP Viral Immunotherapy Mfg. Facility

88,000 sq.-ft. facility in Andover, MA will support multi-product pipeline of intratumorally and intravenously administered viral immunotherapies.

By: Contract Pharma

Contract Pharma Staff

Oncorus, Inc., a clinical stage biopharmaceutical company developing next-gen viral immunotherapies for cancer, has signed a 15-year lease to build a state-of-the-art, 88,000 sq.-ft. GMP viral immunotherapy clinical manufacturing facility in Andover, MA.   Oncorus has a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple cancer indications with significant unmet needs based on its oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platf...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters